-
Mashup Score: 13Podcast: What Challenges Will Oncologists Face in 2025? - 3 month(s) ago
Dr. Nathan Pennell and Dr. John Sweetenham discuss the evolving landscape of oncology in 2025 and the challenges oncologists will be facing, including the impact of Medicare drug price negotiations, ongoing drug shortages, and the promising role of AI and telehealth in improving patient outcomes and access to clinical trials.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 9Understanding and Integrating Emerging Targets Into Treatment Decision-Making for Metastatic CRC - 3 month(s) ago
The landscape of metastatic colorectal cancer (CRC) treatment is rapidly evolving, with the development of new therapeutic strategies targeting several molecular drivers of CRC progression, including HER2, KRAS, RET, and NTRK. A broader adoption of comprehensive genomic profiling through next-generation sequencing and liquid biopsy will be paramount to advance our understanding of mechanisms of resistance and disease progression.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
The landscape of metastatic CRC treatment is evolving w/ the development of new therapeutic strategies targeting molecular drivers of CRC progression. @jaypsv & @GillSharlene examine the significance of these emerging targets for #ASCODailyNews: https://t.co/GU7L0iQfMv #crcsm https://t.co/KsbLAI6eYo
-
-
Mashup Score: 29
Colorectal cancer (CRC) is the leading cause of cancer-related death among men aged 20 to 39, with a similar trend is seen among young women. Multidisciplinary care is particularly critical for patients with early-onset CRC because of several nuances in their care and should include various disciplines—from clinical care teams to social workers and patient advocacy—to offer well-rounded and patient-focused care.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
✳️Proud of my mentees @MeghanaSinghMD and Dr Dulak who put this #ASCODailyNews editorial together in which we provided insights on sobering facts of young onset CRC in the U.S. ‼️ @ASCO Here are some important points👇 https://t.co/cDRVrla8He
-
-
Mashup Score: 2Uptake of Aspirin as Lynch Syndrome Chemoprevention Remains Low. What Oncologists Need to Know to Support Patients - 4 month(s) ago
Only about one-third of patients with Lynch syndrome are using aspirin or nonsteroidal anti-inflammatory agents as a form of chemoprevention, according to a new study published in JCO Precision Oncology.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Only about 1/3 of patients w/ #LynchSyndrome are using aspirin/NSAIDs as a form of chemoprevention, according to a recent study published in @JCOPO_ASCO. #ASCODailyNews covers the study & discusses what oncologists need to know to support patients: https://t.co/Y9ajkWt9UF https://t.co/mwz6cpUYpf
-
-
Mashup Score: 9Adoptive Cell Therapy in Solid Tumors: How Can We Mitigate Risk and Optimize Rewards? - 4 month(s) ago
Although immune checkpoint inhibitor therapy has revolutionized the treatment of solid tumors, immunologically “cold” tumors remain difficult to treat. Adoptive cell therapy—particularly, tumor-infiltrating lymphocyte therapy—shows promise in this space.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
When it comes to adoptive cell therapy for solid tumors, how can we mitigate the risks and optimize the rewards? @BiachiTiago of @MoffittNews explores the various challenges around ACT in a new editorial for #ASCODailyNews: https://t.co/KoiBDM9vNq https://t.co/RQGB2vSMj7
-
-
Mashup Score: 1Adoptive Cell Therapy in Solid Tumors: How Can We Mitigate Risk and Optimize Rewards? - 4 month(s) ago
Although immune checkpoint inhibitor therapy has revolutionized the treatment of solid tumors, immunologically “cold” tumors remain difficult to treat. Adoptive cell therapy—particularly, tumor-infiltrating lymphocyte therapy—shows promise in this space.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
When it comes to adoptive cell therapy for solid tumors, how can we mitigate the risks and optimize the rewards? @BiachiTiago of @MoffittNews explores the various challenges around ACT in a new editorial for #ASCODailyNews: https://t.co/KoiBDM9vNq https://t.co/RQGB2vSMj7
-
-
Mashup Score: 32Comprehensive Genomic Profiling Improves Precision Therapy Use and Patient Survival - 4 month(s) ago
Two-thirds of patients with advanced cancer whose biopsies were tested using an in-house comprehensive genomic profiling assay were found to be candidates for precision therapies, according to a study at a large U.S. health system. The study also found a survival advantage among patients who received targeted therapies versus those who received chemotherapy alone.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Comprehensive Genomic Profiling Improves Precision Therapy Use and Patient Survival https://t.co/AjCFIQQ2bC @asco
-
-
Mashup Score: 28Comprehensive Genomic Profiling Improves Precision Therapy Use and Patient Survival - 4 month(s) ago
Two-thirds of patients with advanced cancer whose biopsies were tested using an in-house comprehensive genomic profiling assay were found to be candidates for precision therapies, according to a study at a large U.S. health system. The study also found a survival advantage among patients who received targeted therapies versus those who received chemotherapy alone.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Comprehensive Genomic Profiling Improves Precision Therapy Use and Patient Survival https://t.co/AjCFIQQ2bC @asco
-
-
Mashup Score: 26Comprehensive Genomic Profiling Improves Precision Therapy Use and Patient Survival - 4 month(s) ago
Two-thirds of patients with advanced cancer whose biopsies were tested using an in-house comprehensive genomic profiling assay were found to be candidates for precision therapies, according to a study at a large U.S. health system. The study also found a survival advantage among patients who received targeted therapies versus those who received chemotherapy alone.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Comprehensive Genomic Profiling Improves Precision Therapy Use and Patient Survival https://t.co/AjCFIQQ2bC @asco
-
-
Mashup Score: 26Comprehensive Genomic Profiling Improves Precision Therapy Use and Patient Survival - 4 month(s) ago
Two-thirds of patients with advanced cancer whose biopsies were tested using an in-house comprehensive genomic profiling assay were found to be candidates for precision therapies, according to a study at a large U.S. health system. The study also found a survival advantage among patients who received targeted therapies versus those who received chemotherapy alone.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Comprehensive Genomic Profiling Improves Precision Therapy Use and Patient Survival https://t.co/AjCFIQQ2bC @asco
-
đź”®@n8pennell of @ClevelandClinic & Dr. John Sweetenham discuss the top challenges oncologists will face in 2025 + technology's potential to truly improve patient outcomes on the latest episode of the #ASCODailyNews Podcast: https://t.co/oDjFFXd0mc #OncTwitter https://t.co/cbnlKgAgR4